PANTHERx® to Dispense KISQALI® for Metastatic Breast Cancer

PANTHERx will dispense KISQALI® (ribociclib) as a first-line treatment for postmenopausal women with an advanced form of breast cancer.

The Food and Drug Administration has approved KISQALI® as a once-daily oral treatment in combination with an aromatase inhibitor for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.

Full prescribing information can be found at:
https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/kisqali.pdf

PANTHERx® named as finalist for Patient Choice Awards by Specialty Pharmacy Times and Zitter Health Insights

We are proud to announce that Specialty Pharmacy Times and Zitter Health Insights have selected PANTHERx® as a finalist in the Non-PBM/Payer Specialty Pharmacy category. PANTHERx® Specialty Pharmacy’s inclusion as a finalist is based on 2016 results from Patient Satisfaction Survey results in 2016 conducted by Zitter Health Insights.

View the full release here: http://www.businesswire.com/news/home/20170316005889/en/

PANTHERx® looks forward to the awards luncheon on May 2, 2017 at the Asembia Conference.